Следене
Ludwig Kappos
Ludwig Kappos
University of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
Потвърден имейл адрес: uhbs.ch - Начална страница
Заглавие
Позовавания
Позовавания
Година
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ...
Annals of neurology 69 (2), 292-302, 2011
113592011
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ...
The Lancet Neurology 17 (2), 162-173, 2018
81012018
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
67382005
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ...
New England Journal of Medicine 354 (9), 899-910, 2006
41782006
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
40972014
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
L Kappos, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, ...
New England Journal of Medicine 362 (5), 387-401, 2010
33302010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ...
New England Journal of Medicine 362 (5), 402-415, 2010
28742010
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New england journal of medicine 376 (3), 209-220, 2017
21422017
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ...
New England Journal of Medicine 367 (12), 1098-1107, 2012
21402012
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
20712017
Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ...
Nature Reviews Neurology 14 (10), 577-589, 2018
18192018
Oral fingolimod (FTY720) for relapsing multiple sclerosis
L Kappos, J Antel, G Comi, X Montalban, P O'Connor, CH Polman, T Haas, ...
New England Journal of Medicine 355 (11), 1124-1140, 2006
13222006
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ...
New England Journal of Medicine 365 (14), 1293-1303, 2011
13162011
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ...
Annals of neurology 81 (6), 857-870, 2017
11392017
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
M Filippi, MA Rocca, O Ciccarelli, N De Stefano, N Evangelou, L Kappos, ...
The Lancet Neurology 15 (3), 292-303, 2016
11222016
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
10842018
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ...
Neurology 67 (7), 1242-1249, 2006
10492006
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ...
Multiple Sclerosis Journal 24 (2), 96-120, 2018
10362018
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
PL De Jager, X Jia, J Wang, PIW De Bakker, L Ottoboni, NT Aggarwal, ...
Nature genetics 41 (7), 776-782, 2009
10302009
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or, F Barkhof, M Yin, ...
The Lancet 378 (9805), 1779-1787, 2011
9772011
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20